tradingkey.logo
tradingkey.logo
Buscar

Illumina Inc

ILMN
Añadir a la lista de seguimiento
145.475USD
-0.225-0.15%
Horarios del mercado ETCotizaciones retrasadas 15 min
22.11BCap. mercado
26.28P/E TTM

Más Datos de Illumina Inc Compañía

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Información de Illumina Inc

Símbolo de cotizaciónILMN
Nombre de la empresaIllumina Inc
Fecha de salida a bolsaJun 28, 2000
Director ejecutivoThaysen (Jacob)
Número de empleados8970
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección5200 Illumina Way
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92122
Teléfono18582024500
Sitio Webhttps://www.illumina.com
Símbolo de cotizaciónILMN
Fecha de salida a bolsaJun 28, 2000
Director ejecutivoThaysen (Jacob)

Ejecutivos de Illumina Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
40.31K
+38.25%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
22.38K
+25.25%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
--
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
20.91K
-0.57%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
--
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Director
Independent Director
15.19K
--
Ms. Susan E. (Sue) Siegel
Ms. Susan E. (Sue) Siegel
Independent Director
Independent Director
14.46K
--
Mr. Kevin Pegels
Mr. Kevin Pegels
Chief of Global Operations
Chief of Global Operations
13.13K
+37.39%
Mr. Ankur Dhingra
Mr. Ankur Dhingra
Chief Financial Officer
Chief Financial Officer
13.05K
+36.02%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
40.31K
+38.25%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
22.38K
+25.25%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
--
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
20.91K
-0.57%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
--
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
3.23B
74.30%
Services and Other revenue
634.00M
14.60%
Instruments
482.00M
11.10%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.24B
51.65%
Europe
1.26B
29.10%
Asia, Middle East, and Africa
430.00M
9.90%
Greater China
243.00M
5.60%
Americas
163.00M
3.75%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
3.23B
74.30%
Services and Other revenue
634.00M
14.60%
Instruments
482.00M
11.10%

Estadísticas de accionistas

Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
13.29%
BlackRock Institutional Trust Company, N.A.
8.69%
Vanguard Portfolio Management, LLC
4.51%
Vanguard Capital Management, LLC
4.36%
State Street Investment Management (US)
4.09%
Otro
65.06%
Accionistas
Accionistas
Proporción
Capital World Investors
13.29%
BlackRock Institutional Trust Company, N.A.
8.69%
Vanguard Portfolio Management, LLC
4.51%
Vanguard Capital Management, LLC
4.36%
State Street Investment Management (US)
4.09%
Otro
65.06%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
62.42%
Investment Advisor/Hedge Fund
26.91%
Hedge Fund
10.15%
Pension Fund
3.23%
Research Firm
2.53%
Bank and Trust
1.87%
Sovereign Wealth Fund
0.41%
Family Office
0.33%
Individual Investor
0.21%

Participación institucional

Actualizado: dom., 5 de abr
Actualizado: dom., 5 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
1879
162.52M
107.41%
-15.36M
2025Q4
1874
161.12M
105.45%
-20.88M
2025Q3
1888
158.57M
103.78%
-23.77M
2025Q2
1978
167.87M
109.04%
-18.11M
2025Q1
2072
170.79M
107.89%
-16.32M
2024Q4
2074
166.23M
104.94%
-15.71M
2024Q3
2038
151.41M
95.06%
-11.30M
2024Q2
2033
149.41M
93.80%
-18.06M
2024Q1
2096
153.02M
96.09%
-8.97M
2023Q4
2134
150.48M
94.76%
-5.28M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
20.10M
13.15%
+124.32K
+0.62%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
13.15M
8.6%
+8.91K
+0.07%
Dec 31, 2025
State Street Investment Management (US)
6.19M
4.05%
+190.32K
+3.17%
Dec 31, 2025
WCM Investment Management
4.07M
2.66%
-110.36K
-2.64%
Dec 31, 2025
AQR Capital Management, LLC
4.43M
2.89%
+1.03M
+30.26%
Dec 31, 2025
Loomis, Sayles & Company, L.P.
4.17M
2.73%
-115.71K
-2.70%
Dec 31, 2025
Corvex Management LP
3.83M
2.5%
--
--
Dec 31, 2025
Sessa Capital
3.40M
2.23%
-1.28M
-27.37%
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco Biotechnology & Genome ETF
6.09%
Global X Genomics & Biotechnology ETF
5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.96%
First Trust NYSE Arca Biotechnology Index Fund
4.42%
ARK Genomic Revolution ETF
4.38%
VanEck Biotech ETF
3.09%
Alger Russell Innovation ETF
2.61%
First Trust NASDAQ Pharmaceuticals ETF
2.39%
iShares Health Innovation Active ETF
2.29%
First Trust Health Care Alphadex Fund
2.27%
Ver más
Invesco Biotechnology & Genome ETF
Proporción6.09%
Global X Genomics & Biotechnology ETF
Proporción5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción4.96%
First Trust NYSE Arca Biotechnology Index Fund
Proporción4.42%
ARK Genomic Revolution ETF
Proporción4.38%
VanEck Biotech ETF
Proporción3.09%
Alger Russell Innovation ETF
Proporción2.61%
First Trust NASDAQ Pharmaceuticals ETF
Proporción2.39%
iShares Health Innovation Active ETF
Proporción2.29%
First Trust Health Care Alphadex Fund
Proporción2.27%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI